低分子肝素钙治疗早发型重度子痫前期临床疗效观察

目的 观察低分子肝素钙治疗早发型重度子病前期临床疗效.方法 选取孕龄26～34周重度子痫前期患者60例,分为观察组28例和对照组32例,观察组在常规治疗基础上加用低分子肝素钙,对比两组治疗后延长孕龄时间、脐动脉S/D比值、羊水指数、胎盘重量、新生儿体质量及Apgar评分间的差异.结果 平均延长孕龄时间观察组与对照组比较差异有统计学意义(10.19±4.57)d与(6.14±3.56)d,t=3.872,P＜0.01].脐动脉S/D比值、羊水指数、胎盘重量、新生儿体质量,两组比较差异均有统计学意义(t值分别为9.056、5.259、2.157,2.027;P ＜0.01,＜0.05).1分钟及5分钟新生儿Apgar评分提高,两组比较差异均有统计学意义(x2值分别为8.058、7.190,P均＜0.01).结论 应用低分子肝素钙治疗早发型重度子痫前期可延长孕龄,增加新生儿体质量,有效改善新生儿预后.

The clinical effect of low molecular heparin calcium on early onset severe pre-eclampsia

Objective To analyze the clinical effects of low molecular heparin calcium on early onset severe pre-eclampsia.Methods Sixty patients with early onset severe pre-eclampsia at 26-34 weeks of gestational age were divided into treatment group(28 cases)and control group(32 cases).The conventional treatment was delivered in control group and low molecalar heparin calcium(LMWHC)was used in treatment group additionally.The time of prolonged gestational age,umbilical arterial S/D ratio,amniotic fluid index,placenta weight,neonatal weight and Apgar score were measured in two groups.Results The time of prolonged gestational age was 10.19 ±4.57days in treatment group and 6.14 ±3.56 days in control group,which were significantly different(P ＜ 0.01).Umbilical arterial S/D ratio,amniotic fluid index,placenta weight and neonatal weight were all significantly different between the two groups(P ＜ 0.05).Neonatal Apgar score in treatment group was remarkably improved(P ＜ 0.01).Conclusion LMWHC treatment in the patients with early onset severe pre-eclampsia could extend gestational age,increase neonatal weight and improve perinatal outcomes.